Shimokata K, Suetsugu S, Umeda H, Inada S, Torikai K, Morishita M, Wada M, Yamamoto M, Yamori S, Kishimoto H
Jpn J Antibiot. 1986 Nov;39(11):2897-913.
T-2588 was used on 55 patients with respiratory tract infections and 44 cases were evaluated; 23 patients with pneumonia, 12 patients with acute bronchitis, 2 patients with chronic bronchitis, 1 patient with diffuse panbronchiolitis and 6 patients with bronchiectasis with infection. Clinical effects of T-2588 were as follows; excellent in 6 and good in 28 patients. The efficacy rate was 77.3% (34/44). Bacteriological effects of T-2588 were prominent in 8 patients infected with B. catarrhalis, H. influenzae, K. pneumoniae and E. coli, but not in a patient infected with P. putida. The elimination rate was 90.0% (9/10 strains). As side effects, stomatitis, anorexia, diarrhea X vomiting and pruritus were observed in one patient each. Abnormal laboratory findings were observed in 4 patients with elevated GOT and/or GPT. These side effects and abnormal laboratory findings were not serious. The usefulness of T-2588 was 68.2% (30/44). Therefore, T-2588 is a useful drug and its effects are promising in clinical management of respiratory tract infections.
T - 2588用于55例呼吸道感染患者，对44例进行了评估；其中肺炎患者23例，急性支气管炎患者12例，慢性支气管炎患者2例，弥漫性泛细支气管炎患者1例，支气管扩张伴感染患者6例。T - 2588的临床效果如下：6例为优，28例为良。有效率为77.3%（34/44）。T - 2588对8例感染卡他莫拉菌、流感嗜血杆菌、肺炎克雷伯菌和大肠杆菌的患者细菌学效果显著，但对1例感染恶臭假单胞菌的患者无效。清除率为90.0%（9/10株）。作为副作用，分别有1例患者出现口腔炎、厌食、腹泻、呕吐和瘙痒。4例患者出现实验室检查异常，谷草转氨酶和/或谷丙转氨酶升高。这些副作用和实验室检查异常并不严重。T - 2588的有效率为68.2%（30/44）。因此，T - 2588是一种有用的药物，其在呼吸道感染的临床治疗中效果可期。
